Liraglutide vs Retatrutide Side Effects: A Head-to-Head Comparison for Women

What Is the Core Difference Between Liraglutide and Retatrutide?

Liraglutide is a single GLP-1 receptor agonist with roughly two decades of clinical history. Retatrutide is a newer triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. That extra receptor activity is why retatrutide produces roughly three times the weight loss in trials, but it also means a broader pharmacological footprint and a less mature long-term safety record.

Understanding what each drug does at the receptor level helps you predict the side-effect pattern you are likely to experience.

How Liraglutide Works

Liraglutide binds to GLP-1 receptors in the gut, pancreas, and brain. In the gut, it slows gastric emptying and reduces appetite. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon. The net effect on body weight is modest but meaningful: 8.0% mean body-weight loss at 56 weeks in the SCALE Obesity trial, which enrolled 3,731 adults with a BMI of at least 30 (or 27 with a weight-related comorbidity).

How Retatrutide Works

Retatrutide adds GIP and glucagon receptor agonism on top of GLP-1. The glucagon component accelerates hepatic fat burning and raises basal metabolic rate. The GIP component appears to amplify insulin secretion and may reduce nausea compared with GLP-1-only agents, though the clinical evidence on nausea mitigation is mixed. In the Jastreboff et al. Phase 2 NEJM 2023 trial, participants receiving 12 mg weekly lost a mean of 24.2% of body weight by 48 weeks. That is a larger effect than any approved single agent has produced in randomized controlled trial data to date.

Side-Effect Profiles: What Each Drug Actually Does to Your Body

The side-effect overlaps are substantial. Both drugs cause GI disturbances, especially during dose escalation. The differences lie in frequency, severity, and the extra effects that retatrutide's glucagon arm introduces.

Gastrointestinal Side Effects

This is where most women's day-to-day experience diverges from the clinical summaries.

Liraglutide: In the SCALE Obesity trial, nausea occurred in approximately 39.3% of liraglutide participants vs 13.8% on placebo. Vomiting was reported in 15.7% vs 3.9%. Diarrhea affected 20.9% vs 9.9%. Constipation was also more common with liraglutide (19.4% vs 8.5%). Most GI events were mild to moderate, peaked in the first 4 to 8 weeks, and resolved without stopping treatment.

Retatrutide: The Phase 2 trial reported nausea in 45% to 65% of participants across dose groups during escalation, with the highest rates in the 12 mg arm. Vomiting occurred in roughly 20% to 30%. Diarrhea was reported similarly to liraglutide. The glucagon-receptor activity may blunt nausea somewhat at steady state, but the dose-escalation phase appears rougher than liraglutide based on trial-reported adverse event timelines.

The honest summary: retatrutide causes more nausea during ramp-up, and liraglutide causes less weight loss but a marginally smoother GI trajectory for most women.

Cardiovascular and Heart Rate Effects

Liraglutide is associated with a small but consistent increase in resting heart rate of 2 to 3 beats per minute, documented in the LEADER cardiovascular outcomes trial. This matters if you have a history of supraventricular tachycardia or use stimulant medications.

Retatrutide's glucagon agonism adds a second mechanism that can raise heart rate, as glucagon has direct chronotropic effects. Phase 2 data showed mean heart-rate increases of approximately 5 to 6 beats per minute in the 12 mg group. Phase 3 cardiovascular outcome data are not yet available.

Injection-Site Reactions

Both drugs are given subcutaneously. Liraglutide is dosed daily; retatrutide is dosed weekly. Injection-site reactions (redness, nodules, bruising) appear more frequently with retatrutide in Phase 2 data, possibly because the formulation is more concentrated at the injection point. Daily liraglutide injections distribute smaller volumes more frequently, which may reduce local reactions per injection.

Hypoglycemia Risk

In women without diabetes, hypoglycemia is uncommon with both agents because GLP-1 stimulates insulin secretion only when glucose is elevated (glucose-dependent mechanism). However, women with PCOS who are also prescribed metformin or insulin sensitizers should be aware that combining agents can lower blood glucose further, particularly during fasting periods or intense exercise.

Gallbladder Disease

Rapid weight loss from either agent increases the risk of gallstones. A meta-analysis of GLP-1 receptor agonists found a modest increase in cholelithiasis risk (odds ratio approximately 1.2 to 1.4 across agents). Women are already at higher baseline risk for gallstones than men, especially during reproductive years when estrogen elevates biliary cholesterol. This risk compounds with retatrutide given the greater magnitude of weight loss.

Weight Loss Magnitude: What the Trial Data Actually Show

No head-to-head randomized controlled trial comparing liraglutide directly with retatrutide exists as of early 2025. All comparisons here are cross-trial and should be interpreted carefully, because trial populations, dose-escalation schedules, and follow-up durations differ.

SCALE Obesity (Liraglutide)

The SCALE Obesity trial, published in the New England Journal of Medicine in 2015, randomized 3,731 adults to liraglutide 3.0 mg daily or placebo, both with lifestyle counseling. At 56 weeks, liraglutide participants lost a mean of 8.0% of body weight vs 2.6% with placebo. Approximately 63.2% of liraglutide participants lost at least 5% of body weight.

Jastreboff Phase 2 (Retatrutide)

The Jastreboff et al. Phase 2 trial, published in NEJM in 2023, randomized 338 adults with obesity (BMI 30 to 50) to retatrutide or placebo at doses of 1, 4, 8, or 12 mg weekly, with a 24-week dose escalation. At 48 weeks, the 12 mg group achieved a mean weight reduction of 24.2%. The 8 mg group lost 22.8%. These figures are numerically similar to what bariatric surgery produces in some series.

What This Means for You

If your goal is 5 to 10% weight reduction to improve insulin resistance, menstrual regularity in PCOS, or cardiovascular risk factors, liraglutide's track record of 8% may be adequate. If you have severe obesity (BMI above 40) or have not responded well to single-receptor GLP-1 agents, retatrutide's greater efficacy is clinically meaningful. Retatrutide is not yet FDA-approved, so access currently involves clinical trials or compounding (with all the quality-control caveats that entails).

Women-Specific Considerations: PCOS, Perimenopause, and Beyond

Sex-specific data on these agents remain limited. Both the SCALE and Jastreboff trials enrolled predominantly female participants (approximately 75 to 80% women in SCALE; the Jastreboff trial did not break down sex-stratified weight-loss outcomes in the primary publication), but neither trial reported sex-stratified side-effect frequencies. This is an evidence gap women deserve to know about.

Reproductive Years and PCOS

GLP-1 receptor agonists improve insulin sensitivity and lower androgen levels in women with PCOS. Liraglutide has been studied specifically in PCOS populations: a 2018 randomized trial published in Fertility and Sterility found that liraglutide 1.2 mg daily reduced body weight, fasting insulin, and free androgen index over 12 weeks. Improved menstrual regularity was observed in some women, likely secondary to weight-related androgen reduction.

Retatrutide has not been studied specifically in PCOS as of early 2025. Its triple-receptor mechanism, particularly the GIP arm, may have additional effects on insulin secretion that benefit PCOS-related hyperinsulinemia, but this is extrapolated from mechanism rather than trial data.

Women with PCOS should also know that weight loss from either agent may restore ovulation. If pregnancy is not desired, effective contraception is essential from day one of treatment.

Perimenopause and Post-Menopause

Perimenopausal weight gain concentrates preferentially in the abdomen as estrogen declines. GLP-1 receptor agonists reduce visceral fat, which may offer cardiovascular benefit in this life stage. Liraglutide has no published menopausal-specific RCT data, and retatrutide has none at all. The glucagon component of retatrutide raises basal metabolic rate, which is theoretically appealing in the post-menopausal context of reduced resting energy expenditure, but this has not been studied in women stratified by menopausal status.

Perimenopausal women on hormone therapy (HT) should be aware that estrogen affects gastric motility. Adding a GLP-1 agent that slows gastric emptying on top of estrogen-related GI sensitivity may worsen nausea in the first weeks of treatment.

Thyroid Considerations

Liraglutide carries an FDA black box warning for thyroid C-cell tumors based on rodent data. It is contraindicated in women with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Retatrutide carries the same class warning based on its GLP-1 activity.

Women with Hashimoto's thyroiditis (the most common autoimmune thyroid condition) are not specifically contraindicated, but thyroid function should be monitored because significant weight loss changes thyroxine distribution and may require TSH rechecks and dose adjustments.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Both liraglutide and retatrutide are contraindicated during pregnancy. This is not a soft caution. Stop either drug at least two months before attempting conception.

Liraglutide in Pregnancy

Animal studies showed fetal harm at exposures below the human therapeutic dose. Human data are extremely limited. The FDA prescribing label recommends discontinuing liraglutide at least one to two months before a planned pregnancy. There is no safe dose in pregnancy.

Retatrutide in Pregnancy

Retatrutide is investigational and has no approved prescribing label. Based on GLP-1 class effects and the animal data pattern established for liraglutide and semaglutide, reproductive risk is expected. Women of reproductive age enrolled in the Jastreboff Phase 2 trial were required to use effective contraception throughout. Until Phase 3 reproductive-safety data are published, assume this drug carries the same pregnancy contraindication as other GLP-1 agents.

Lactation

Liraglutide is a large peptide (molecular weight approximately 3,751 daltons). Animal studies suggest low transfer into milk, but no adequate human lactation data exist. Given the lack of safety data, liraglutide is not recommended during breastfeeding. Retatrutide lactation data do not exist. The conservative clinical standard is to avoid both agents while breastfeeding.

Contraception Requirement

Any woman of reproductive potential starting liraglutide or (if enrolled in a trial) retatrutide should use reliable contraception. GLP-1 agents slow gastric emptying, which may reduce absorption of oral contraceptive pills, particularly during dose escalation. The ACOG guidance on GLP-1 agents recommends counseling women on this interaction. Options with no absorption concern include IUDs, implants, injections, or barrier methods used alongside any oral pill during the ramp-up period.

Who Is Liraglutide Right For, and Who Should Consider Retatrutide?

Liraglutide May Be the Better Starting Point If You:

• Have a BMI of 27 to 35 with one or more weight-related comorbidities (PCOS, hypertension, prediabetes)
• Are in your reproductive years and want a drug with more clinical history in women
• Need FDA-approved treatment (liraglutide is approved; generic liraglutide is now available)
• Have a history of mild to moderate GI sensitivity and want a slower, lower-intensity ramp
• Are approaching perimenopause and want an agent with established cardiovascular data from the LEADER trial

Retatrutide May Be More Appropriate If You:

• Have severe obesity (BMI above 40) and have not achieved adequate response with liraglutide or semaglutide
• Are eligible and interested in enrolling in an ongoing Phase 3 clinical trial
• Have obesity-related type 2 diabetes and may benefit from the stronger glucose-lowering effect
• Understand and accept that long-term safety data, especially for women, do not yet exist

Who Should Not Use Either Drug:

• Pregnant women (contraindicated)
• Women currently breastfeeding (insufficient safety data)
• Women with a personal or family history of MTC or MEN2
• Women with a history of pancreatitis (both agents carry a pancreatitis warning)
• Women with severe gastroparesis (gastric-emptying slowing worsens this condition)

Can You Switch From Liraglutide to Retatrutide?

No clinical trial has prospectively studied switching from liraglutide to retatrutide, so there is no evidence-based washout or titration protocol. Based on the mechanism, switching would mean transitioning from a daily GLP-1 agonist to a weekly triple agonist with a new dose escalation from scratch. Clinicians who manage off-label compounded GLP-1 switching typically allow at least a one-week washout from liraglutide before starting low-dose retatrutide escalation, though this is expert practice, not guideline-supported protocol.

Women switching during active perimenopause or while using hormone therapy should discuss timing with their prescriber, because layering GI side effects from a new escalation on top of hormonal GI fluctuations (bloating, nausea common in perimenopause) can be difficult to manage.

Evidence Gaps Women Should Know About

Women have been historically under-represented in weight-management and metabolic trials. Neither the SCALE nor the Jastreboff Phase 2 trial published sex-stratified subgroup analyses for the primary efficacy or side-effect endpoints. This means the headline weight-loss numbers (8.0% and 24.2%) may not reflect what women specifically lose. The adverse-event rates may also differ by sex, as women tend to experience GI side effects from GLP-1 agents more intensely than men in the limited sex-stratified data available from other GLP-1 trials.

Life-stage stratification is almost entirely absent. No trial has reported outcomes separately for women in reproductive years, perimenopausal women, or post-menopausal women. No trial has reported outcomes stratified by PCOS status, menopausal hormone therapy use, or menstrual cycle phase at initiation.

The ACOG position on GLP-1 agents acknowledges this gap and calls for sex-disaggregated reporting in future metabolic trials. Until those data exist, the evidence base for choosing between these two agents in women is necessarily extrapolated from mixed-sex trial populations.

Dosing and Practical Differences That Affect Daily Life

Liraglutide requires a daily injection, which some women find burdensome long-term. The pen device is well-established and generic versions are now available in the US, making liraglutide significantly more affordable than branded semaglutide (Ozempic/Wegovy) and far more accessible than retatrutide, which requires trial enrollment or a compounding pharmacy with no FDA-quality oversight.

Retatrutide's once-weekly schedule is more convenient but the dose-escalation phase is longer (the Jastreboff trial used a 24-week escalation) and requires clinical supervision throughout. The higher injection volume at the 12 mg dose is associated with more local reactions than the small daily liraglutide volume.